JSCR Journal of Surgical Case Reports
doi: 10.1093/jscr/rjaa211 Case Report
CASE REPORT
Adrenocortical sarcomatoid carcinoma: a case report and review of the literature
Derqaoui Sabrine*, Bernoussi Zakia, and Znati Kaoutar Department of Pathology, Ibn Sina Teaching Hospital, Rabat, Morocco
*Correspondence address. Department of Pathology, Ibn Sina Teaching Hospital, Abderrahim Bouabid Avenue, Rabat, Morocco. Tel: +212537676464; Fax:+212537775856; E-mail: s.derqaoui@gmail.com
Abstract
Adrenal sarcomatoid carcinoma (ASC) is a very rare aggressive variant of adrenocortical carcinoma showing carcinomatous and sarcomatous differentiation. It is a poorly differentiated carcinoma with poor prognosis. The diagnosis requires careful histological and immunohistochemical investigation. We describe a new case of ASC to raise awareness on this extremely rare entity. A 27-year-old woman presented with a right flank pain. Imaging revealed a tissular mass of the right adrenal gland without metastases. After adrenalectomy, histology revealed sheets of epithelioid cells that stained for synaptophysin and Melan-A; and spindled cells staining for S-100. We have reported the clinical and histopathological features of ACS’s case; as it is an extremely rare cancer with a challenging diagnosis. There is a need for a further understanding of ASC’s biology to improve it poor prognosis.
INTRODUCTION
Adrenal sarcomatoid carcinomas (ASC) are rare aggressive malignant neoplasms of the adrenal gland, showing both carcinomatous and mesenchymal differentiation [1]. It has a poor prognosis as most of patients have distant metastasis at the time of diagnosis [2]. The first case of ASC was reported in 1989 by Collina et al. [3]. To the best of our knowledge, only 20 cases have been reported in the English literature to date [1]. Herein, we describe a new case of an ASC and a review of the literature to raise awareness on this extremely rare entity which presents with a diagnostic challenge.
CASE PRESENTATION
A 27-year-old woman presented with a 6 months history of a right flank pain and a moderate weight loss. She had no remark- able medical history. Upon physical examination, she had stable
vital signs, without adrenal hormonal hypersecretion’s signs. The patient’s blood cell counts, serum electrolyte levels, renal and liver functions, 24-h urinary catecholamines, cortisol, testos- terone, dihydroxyepiandrosterone sulfate and aldosterone levels were all within normal limits. Abdominal computed tomography (CT) scan showed a 12.5 x 9 x 7.5 cm tissular heterogeneous mass, with irregular borders, of the right adrenal gland, with cal- cifications (Fig. 1). The routine staging was negative for metas- tases.
She underwent an adrenalectomy. On gross, the specimen weighed 660 g and measured 12 x 9 x 7 cm. It was well cir- cumscribed, firm, beige-colored, with extensive hemorrhage and necrosis at sectioning; completely effacing the adrenal gland. Hematoxylin-eosin stained sections revealed diffuse sheets of epithelioid and pleomorphic/spindled cells. The epithelioid com- ponent consisted of sheets and nests of polygonal cells with clear and eosinophilic (40%) cytoplasm resembling adrenocor- tical cells with loss of lobulation (Fig. 2A). There was marked
= 210 L=57
1:05:28 ilt: 0.0
.2mm 1.75:1/1.25sp
ot 0.80s/HE. 35.0mm/rot
A Mod.
V 120
.0/Average
STHD. SS
DFOV
4
hoothl
I 325
calculées sur les inages originales images Filtrées : mesures
111.2 mm (2D)
68.2 mm (2D)
NOHN 1
W = 210 L = 57
01:05:28
Tilt: 0.0
1.2mm 1.75:1/1.25sp
Rot 0.80s/HE+ 35.0mm/rot
MA Mod.
KV 120
4.0/ Average
STHD/SSBQ Smooth1
DFOV 40.5
&
1 325
calculées sur les images originales
110.9 mm (2D)
Trages filtrées : mesures
nuclear atypia (Nuclear grade III) with high mitotic activity (5/10 high-power fields [HPF]). The pleomorphic component (40% of tumor) consisted of fascicles of spindled and ovoid cells. Nuclei were highly pleomorphic with dense heterogenous chromatin (Fig. 2B). Some multinucleated neoplastic giant cells were iden- tified. The mitotic count was higher (12 mitoses/10 HPF). The Weiss score was 6. On immunohistochemistry, epitheliod cells
showed strong, diffuse positivity with Melan-A and synapto- physin. Spindled cells were focally strongly positive for synapto- physin, Melan-A and PS100 (Fig. 3). Immunostains for AE1/AE3, HMB-45, inhibin, desmin, vimentin, caldesmon and SMA were negative in both components. Unfortunately, genetic analysis was not performed, because it is not available in our institution. After a follow-up of 6 months, there was no evidence of local recurrence on CT.
DISCUSSION
ASC is a very rare malignant tumor [4] (only 20 cases reported in the literature to date) [1]. ASC represents the least common variant of ACC [5]. Primary ASC mainly occurs in middle-aged patients (23-79 years) with a sex ratio (male:female) of 1:1. [6]. Our patient was a middle-aged woman. As in the present case, these carcinomas are usually non-functioning tumors [5] with non-specific symptoms including: abdominal masses; abdominal pain, weight loss and asthenia. When functional, following symptoms may occur including: severe hypertension; Cushing’s syndrome; feminization or masculinization [6]. ASC pre-operative diagnosis remains challenging [7]. Adrenal biopsy is not routinely carried out for suspicious adrenal masses, the accurate diagnosis is made after surgical exploration [8], by histological and immunuhistochemical study [7]. Sarcomatoid carcinoma are composed of malignant epithelial cells and specialized mesenchymal cells. Some cases show osteosar- comatous, rhabdomyosarcomatous or chondrosarcomatous differentiation [4]. The Weiss score is the most widely used sys- tem. It comprises nine parameters: (1) nuclear grade (Fuhrman III or IV), (2) mitotic rate of >5/50 HPFs, (3) abnormal mitoses, three refer to tumor structure (4): >25% clear cells, (5) >1/3 diffuse architecture, (6) necrosis; (7) venous invasion, (8) sinusoidal invasion and (9) capsular invasion. The epithelioid component shows features of conventional ACC and meets four or more of the Weiss histological criteria [2]. In our case, the WEISS score of the epithelioid component was nine and the sarcomatoid component did not show any recognizable differentiation. Definitive diagnosis requires immunostaining. Several markers are of diagnostic value including: Melan-A, synaptophysin, calretinin; as they confirm the adrenal phenotype of the tumor [7]. Epitheliod cells are also immunoreactive for vimentin, inhibin, neuron-specific enolase and occasionally positive for AE1/AE3. The laters are negative for chromogranin and EMA. According to previous studies, sarcomatous component may be positive for desmin, myogenin, HHF35, vimentin, myoglobin, caldesmon, smooth muscle actin, AE1/AE3, EMA, HMB-45, PS 100, inhibin and chromogranin [7, 8]. In the present case, spindled cells were focally positive for synaptophysin and Melan-A. These findings are similar to those reported by Sasaki et al. [7], which supports that sarcomatous component originated from the adrenocortical carcinoma
The histological diagnosis of ASC, especially when mononop- hasic, is challenging. In fact, they can be indistinguishable from adrenal sarcomas and retroperitoneal sarcomas with adrenal extension (e.g. liposarcoma, rhabdomyosarcoma etc) [9]. The dif- ferential diagnosis also includes extra-adrenal carcinosarcomas and metastases with sarcomatoid elements. Thus, the diagnosis is based on a careful histological and immunohistochemical analysis and in some cases, on genetic analysis [7]. Adrenocorti- cal carcinomas show variant genetic aberrations, including gains in chromosomes 4, 5, 7, 12, 16, 19 and 20, and losses involving 1p, 2q, 11q, chromosome 17, 13 and 22 [4]. ASCs are aggres- sive tumors with a very poor prognosis. Frequent metastases
A1
A2
BL
B2
have been reported, post-operative survival ranges from 3 to 12 months after surgical treatment in the majority of patients. The longest postoperative survival (17 months) with no evidence of metastasis was reported by Mark et al. [10]. Radical surgical excision is the only curative treatment. Adjuvant chemother- apy is suggested after the first surgery, when distant metas- tasis or local invasions are absent [8]. To date, no evidence- based consensus have been reported regarding best oncological treatment of ASCs. Epithelial to Mesenchymal Transition (EMT)- related markers and stem cell factors might be novel therapeutic targets [5].
In conclusion, we have reported the clinical and histopatho- logical features of this extremely rare cancer. Up to present, no standard efficient treatment regimens have been clearly identi- fied. There is a need for a further understanding of ASC’s biology to improve its poor prognosis.
ACKNOWLEDGEMENTS
Not applicable.
COMPETING INTERESTS
The authors declare that they have no competing interests.
FUNDING
No funding source was needed.
ETHICS APPROVAL AND CONSENT TO PARTIC- IPATE
Not applicable.
CONSENT
Informed consent was obtained from the patient. Guarantor is the corresponding author.
AVAILABILITY OF DATA AND MATERIALS
Not applicable.
AUTHORS’ CONTRIBUTIONS
All authors read and approved the final manuscript.
A
B
C
D
REFERENCES
1. Ishikawa N, Nagase M, Takami S, Araki A, Ishikawa N, Koike C, et al. Case report of bilateral sarcomatoid carcinoma of adrenal glands with adrenal insufficiency. Int J Surg Pathol 2016;24:743-8.
2. Sturm N, Moulai N, Laverrière M-H, Chabre O, Descotes J- L, Brambilla E. Primary adrenocortical sarcomatoid carci- noma: case report and review of literature. Virchows Arch 2007;452:215-9.
3. Collina G, Maldarizzi F, Betts CM, Eusebi V. Primary sarcoma- toid carcinoma of the adrenal gland. Vichows Archiv A Pathol Anat 1989;415:161-7.
4. Erickson LA. Challenges in surgical pathology of adrenocortical tumours. Histopathology 2017;72: 82-96.
5. Papathomas TG, Duregon E, Korpershoek E, Restuccia DF, van Marion R, Cappellesso R, et al. Sarcomatoid adrenocor- tical carcinoma: a comprehensive pathological, immunohis-
tochemical, and targeted next-generation sequencing anal- ysis. Hum Pathol 2016;58:113-22.
6. Zhu C, Zheng A, Mao X, Shi B, Li X. Primary adrenal sarco- matoid carcinoma metastatic to the lung: case report and review of the literature. Oncol Lett 2016;11:3117-22.
7. Sasaki K, Desimone M, Harsha RR, Huang GJ, Seethala RR. Adrenocortical carcinosarcoma: a case report and review of the literature. Diagn Pathol 2010;5:51.
8. Turhan Iyidir O, Turgay CE, Özkan C, Altınova E, Çimen AR, Sözen S, et al. A case report of bilateral adrenal Sarcomatoid carcinoma. Case Rep Surg 2016;2016:3768258.
9. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs WHO/IARC Classification of Tumours, 4th edn. World Health Organization (IARC): Ulster Medical Society, 2017, 161-7.
10. Mark D, Boyd C, Eatock F. Adrenal sarcomatoid carci- noma: a case report and review of the literature. Ulster Med J 2014;83:89-92.